Palbociclib (PAL) plus letrozole (L) as first-line (1) therapy (tx) in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety across patient (pt) subgroups.

被引：5
|
作者：
Finn, Richard S.
Dieras, Veronique
Rugo, Hope S.
Joy, Anil A.
Moulder, Stacy L.
Walshe, Janice Maria
Mukai, Hirofumi
Shparyk, Yaroslav V.
Park, In Hae
Mori, Ave
Lu, Dongrui
Gauthier, Eric Roland
Gelmon, Karen A.
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Inst Curie, Paris, France
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[4] Cross Canc Inst, Edmonton, AB, Canada
[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] CCRT, Dublin, Ireland
[7] Natl Canc Ctr Hosp East, Chiba, Japan
[8] Lviv State Oncol Reg Med & Diagnost Ctr, Lvov, Ukraine
[9] Natl Canc Ctr, Ctr Breast Canc, Goyangsi, South Korea
[10] Pfizer Srl, Milan, Italy
[11] Pfizer Inc, La Jolla, CA USA
[12] British Columbia Canc Agcy, Vancouver, BC, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1039
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1039
引用
收藏
页数：6
相关论文
共 50 条
  • [1] Palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Efficacy and safety updates with longer follow-up across patient subgroups
    Rugo, Hope S.
    Finn, Richard S.
    Dieras, Veronique
    Ettl, Johannes
    Lipatov, Oleg
    Joy, Anil
    Harbeck, Nadia
    Castrellon, Aurelio
    Lu, Dongrui R.
    Mori, Ave
    Gauthier, Eric R.
    Huang, Cynthia
    Gelmon, Karen A.
    Slamon, Dennis J.
    CANCER RESEARCH, 2018, 78 (04)
  • [2] Palbociclib (PAL) plus letrozole (L) as first-line (1L) therapy (tx) in postmenopausal Asian women with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
    Im, S-A.
    Mukai, H.
    Park, I. H.
    Masuda, N.
    Shimizu, C.
    Kim, S. B.
    Im, Y-H.
    Ohtani, S.
    Bartlett, C. H.
    Lu, D. R.
    Mori, A.
    Gauthier, E.
    Finn, R. S.
    Toi, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Efficacy and safety of palbociclib (PAL) plus letrozole (LET) as first-line therapy in estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Findings by geographic region from PALOMA-2
    Gelmon, Karen A.
    Castrellon, Aurelio
    Joy, Anil A.
    Walshe, Janice M.
    Ettl, Johannes
    Mukai, Hirofumi
    Park, In Hae
    Lu, Dongrui R.
    Mori, Ave
    Bananis, Eustratios
    Dieras, Veronique
    Finn, Richard S.
    CANCER RESEARCH, 2018, 78 (04)
  • [4] PALOMA-2: Neutropenia (NP) patterns in patients (Pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) first-line advanced breast cancer (ABC) receiving palbociclib plus letrozole (P plus L)
    Dieras, V.
    Harbeck, N.
    Joy, A. A.
    Gelmon, K. A.
    Ettl, J.
    Verma, S.
    Lu, D.
    Gauthier, E. R.
    Schnell, P.
    Mori, A.
    Rugo, H. S.
    Finn, R. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] Impact of prior treatment on palbociclib plus letrozole (P plus L) efficacy and safety in patients (pts) with estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) first-line advanced breast cancer (ABC): A PALOMA-2 subgroup analysis
    Finn, R. S.
    Gelmon, K. A.
    Ettl, J.
    Asselah, J.
    Castrellon, A.
    Ruiz Simon, A.
    Joy, A. A.
    Lu, D.
    Gauthier, E. R.
    Mori, A.
    Rugo, H. S.
    Dieras, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    Rugo, H. S.
    Finn, R. S.
    Dieras, V.
    Ettl, J.
    Lipatov, O.
    Joy, A. A.
    Harbeck, N.
    Castrellon, A.
    Iyer, S.
    Lu, D. R.
    Mori, A.
    Gauthier, E. R.
    Bartlett, C. Huang
    Gelmon, K. A.
    Slamon, D. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2019, 174 (03) : 719 - 729
  • [7] Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
    H. S. Rugo
    R. S. Finn
    V. Diéras
    J. Ettl
    O. Lipatov
    A. A. Joy
    N. Harbeck
    A. Castrellon
    S. Iyer
    D. R. Lu
    A. Mori
    E. R. Gauthier
    C. Huang Bartlett
    K. A. Gelmon
    D. J. Slamon
    Breast Cancer Research and Treatment, 2019, 174 : 719 - 729
  • [8] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
  • [9] Alpelisib plus letrozole in estrogen receptor-Positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial
    Juric, Dejan
    Goncalves, Anthony
    Hamilton, Erika
    Boni, Valentina
    Mayer, Ingrid A.
    Turri, Sabine
    Wang, Yingbo
    Vogl, Florian D.
    Sellami, Dalila
    Campone, Mario
    CANCER RESEARCH, 2018, 78 (04)
  • [10] Efficacy and safety of palbociclib (PAL) in patients (pts) with estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) with preexisting conditions: A post hoc analysis of PALOMA-2
    Gelmon, Karen
    Walshe, Janice M.
    Mahtani, Reshma
    Joy, Anil A.
    Karuturi, Meghan
    Neven, Patrick
    Lu, Dongrui Ray
    Kim, Sindy
    Schnell, Patrick
    Bananis, Eustratios
    Schwartzberg, Lee
    CANCER RESEARCH, 2021, 81 (04)
12345